№ lp_2_3_53425
File format: docx
Character count: 2111
File size: 19 KB
Note:
Year
Topic:
Medical Necessity for Genetic Testing
Document Type:
Letter
Target Audience:
Medical Director
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2021
Region:
Australia
Topic:
Pharmacology / Drug utilisation
Document type:
Report
Organization:
Drug Utilisation Sub-Committee (DUSC), Department of Health, Services Australia
Drug:
Tolvaptan
Condition:
Autosomal dominant polycystic kidney disease (ADPKD)
Population:
Adults with chronic kidney disease stage 1–3
Data source:
Pharmaceutical Benefits Scheme (PBS) database
Date of PBS listing:
1 January 2019
Treatment criteria:
Nephrologist management, eGFR 30–89 mL/min/1.73m², evidence of rapidly progressing disease
Monitoring requirements:
Liver function tests prior to initiation, monthly for 18 months, then every 3 months
Dosage forms:
15 mg, 30 mg, 45 mg, 60 mg, 90 mg tablets in split-dose regimens
Analysis period:
First and second year of PBS listing
Note:
Year
Theme:
Neurology, Genetics
Document Type:
Medical Report
Target Audience:
Medical Professionals, Researchers
Contextual Description:
A medical report describing the diagnosis, clinical features, and specimen requirements for the genetic condition CADASIL.
Year:
2021
Region / City:
Zhejiang Province, China
Topic:
Epilepsy, Neuroscience
Document Type:
Research Article
Organization / Institution:
Zhejiang University
Author:
Lin Zhou, Liang Zhou, Li-Da Su, Sheng-Long Cao, Ya-Jun Xie, Ying Shen
Target Audience:
Researchers in neuroscience and epilepsy
Period of Action:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2021
Region:
Australia
Topic:
Pharmacology / Drug utilisation
Document type:
Report
Organization:
Drug Utilisation Sub-Committee (DUSC), Department of Health, Services Australia
Drug:
Tolvaptan
Condition:
Autosomal dominant polycystic kidney disease (ADPKD)
Population:
Adults with chronic kidney disease stage 1–3
Data source:
Pharmaceutical Benefits Scheme (PBS) database
Date of PBS listing:
1 January 2019
Treatment criteria:
Nephrologist management, eGFR 30–89 mL/min/1.73m², evidence of rapidly progressing disease
Monitoring requirements:
Liver function tests prior to initiation, monthly for 18 months, then every 3 months
Dosage forms:
15 mg, 30 mg, 45 mg, 60 mg, 90 mg tablets in split-dose regimens
Analysis period:
First and second year of PBS listing
Note:
Year
Theme:
Neurology, Genetics
Document Type:
Medical Report
Target Audience:
Medical Professionals, Researchers
Contextual Description:
A medical report describing the diagnosis, clinical features, and specimen requirements for the genetic condition CADASIL.
Year:
2021
Region / City:
Zhejiang Province, China
Topic:
Epilepsy, Neuroscience
Document Type:
Research Article
Organization / Institution:
Zhejiang University
Author:
Lin Zhou, Liang Zhou, Li-Da Su, Sheng-Long Cao, Ya-Jun Xie, Ying Shen
Target Audience:
Researchers in neuroscience and epilepsy
Period of Action:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / City:
United Kingdom / Australia
Topic:
Bird breeding genetics
Document type:
Article
Organization / Institution:
N/A
Target Audience:
Bird breeders, fanciers
Period of Validity:
N/A
Approval Date:
N/A
Modification Date:
N/A
Year:
2025
Country:
United States
Type of Document:
Regulatory order
Issuing Authority:
Postal Regulatory Commission
Subject:
Service Performance Measurement Plan revisions
Dockets:
RM2024-9, PI2025-5
Implementation Phases:
Phase 1 – July 1, 2025; Phase 2 – September 1, 2025
Methods:
Cluster sampling, 5-Digit ZIP Code level measurement
Relevant Documents:
SPM Plan, design documents, library references
Target Audience:
Postal Service management and stakeholders
Previous Related Dockets:
N2024-1, PI2025-2
Content Focus:
Statistical measurement and operational changes in postal services
Year:
2021
Region:
Australia
Topic:
Pharmacology / Drug utilisation
Document type:
Report
Organization:
Drug Utilisation Sub-Committee (DUSC), Department of Health, Services Australia
Drug:
Tolvaptan
Condition:
Autosomal dominant polycystic kidney disease (ADPKD)
Population:
Adults with chronic kidney disease stage 1–3
Data source:
Pharmaceutical Benefits Scheme (PBS) database
Date of PBS listing:
1 January 2019
Treatment criteria:
Nephrologist management, eGFR 30–89 mL/min/1.73m², evidence of rapidly progressing disease
Monitoring requirements:
Liver function tests prior to initiation, monthly for 18 months, then every 3 months
Dosage forms:
15 mg, 30 mg, 45 mg, 60 mg, 90 mg tablets in split-dose regimens
Analysis period:
First and second year of PBS listing
Year:
2024
Region / city:
United Kingdom
Topic:
Health, Medical Condition
Document Type:
Patient Information Leaflet
Organization / Institution:
BritSPAG Executive Committee
Author:
BritSPAG Executive Committee
Target Audience:
Teenagers, young adults, individuals with PCOS or at risk
Period of validity:
Ongoing
Approval Date:
January 2024
Date of amendments:
Not specified
Contextual description:
Information leaflet explaining polycystic ovary syndrome (PCOS) in teenagers and young adults, with details on symptoms, diagnosis, treatment options, and resources for support.
Year:
2026
Region / City:
Australia
Document Type:
Informational Article
Organization / Institution:
The PCOS Clinic
Author:
Dr. Rebecca Harwin
Target Audience:
Women of reproductive age
Symptoms Covered:
Irregular menstruation, high testosterone, polycystic ovaries, acne, hirsutism, overweight/obesity, infertility, hair loss, skin changes, fatigue, mood disorders
Medical Focus:
Polycystic Ovary Syndrome (PCOS)
Diagnosis Criteria:
Menstrual irregularities, androgen levels, ultrasound findings, insulin resistance
Consultation Information:
PCOS Discovery Session via The PCOS Clinic
References:
www.ConquerYourPCOSNaturally.com
Note:
, www.ThePCOSClinic.com
Year:
2026
Databases:
PubMed, Embase, Cochrane Library, Web of Science
Topic:
Polycystic ovary syndrome, depression, anxiety
Document type:
Supplementary table
Author:
Not specified
Target population:
Patients with polycystic ovary syndrome and comorbid mental health conditions
Search period:
Up to 2026
Query type:
MeSH terms and title/abstract keywords
Number of results:
PubMed 7631, Embase 24191, Cochrane Library 2611, Web of Science 1114
Year:
2026
Institution:
S. Lal Singh Memorial College of Pharmacy (DBU)
Author:
Ruvaita Showakat
Document Type:
Review Article
Target Audience:
Medical students, healthcare professionals
Condition:
Polycystic Ovary Syndrome (PCOS)
Diagnostic Criteria:
Rotterdam criteria
Management Strategies:
Lifestyle modification, pharmacological therapy
Research Gaps:
Genetic and epigenetic factors, long-term treatment outcomes, population diversity
Future Directions:
Personalized medicine, digital health integration, holistic care